丙酸氟替卡松、孟鲁司特钠、酮替芬治疗小儿咳嗽变异性哮喘的临床疗效观察
2019/05/10
摘要
目的：研究丙酸氟替卡松(Flu)、孟鲁司特钠(Mon)、酮替芬(Ket)联合治疗小儿咳嗽变异性哮喘(CVA)的临床疗效。
方法：将2015年6月至2018年1月呼吸内科收治的280例CVA患儿随机分为Flu+Mon+Ket、Flu+Mon、Flu+Ket、Mon+Ket、Flu、Mon和Ket组，每组40例。每组患儿均给予相应药物治疗，每组疗程均为3个月。观察治疗2、3个月后患者咳嗽情况、咳嗽症状评分、肺功能及药物不良反应情况。随访患儿复发情况。
结果：经过治疗后，所有7组患儿咳嗽症状评分均呈下降趋势，1秒用力呼气量百分比(FEV1%)和预测呼气峰流量百分比(PEF%)均呈上升趋势。治疗2个月后，Flu +Mon+Ket组咳嗽症状评分明显低于其他组，FEV1%和PEF%明显高于其他组(P<0.05)。治疗2、3个月后，Ket组咳嗽症状评分明显高于其他组，FEV1%、PEF%明显低于其他组(P<0.05)。治疗3个月后，各组咳嗽症状评分、FEV1%、PEF%比较无显著性差异(P>0.05)。7组不良事件发生率均较低，7组间差异无统计学意义(P>0.05)。Ket组咳嗽复发率明显高于其他组(P<0.001)，而其他组咳嗽复发率无显著差异(P>0.0024)。
结论：对于CVA患儿来说，丙酸氟替卡松、孟鲁司特钠、酮替芬联合治疗2个月的临床效果优于两种药物联合治疗和单一药物治疗，并且是安全的。经过3个月的治疗，单用丙酸氟替卡松或单用孟鲁司特钠与药物联合治疗的效果相似。单用酮替芬临床疗效差，且停药后复发率高。
Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children.
Zhu XH, Tu JW, Dai JH.
Abstract
OBJECTIVE:To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA).
METHODS:A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence.
RESULTS:After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P<0.05). After 2 and 3 months of treatment, the Ket group had a significantly higher cough symptom score and significantly lower FEV1% and PEF% than the other groups (P<0.05). After 3 months of treatment, there were no significant differences in cough symptom score, FEV1% and PEF% among the other groups (P>0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P>0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P<0.001), while there was no significant difference in this rate among the other groups (P>0.0024).
CONCLUSIONS:For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal.
目的：研究丙酸氟替卡松(Flu)、孟鲁司特钠(Mon)、酮替芬(Ket)联合治疗小儿咳嗽变异性哮喘(CVA)的临床疗效。
方法：将2015年6月至2018年1月呼吸内科收治的280例CVA患儿随机分为Flu+Mon+Ket、Flu+Mon、Flu+Ket、Mon+Ket、Flu、Mon和Ket组，每组40例。每组患儿均给予相应药物治疗，每组疗程均为3个月。观察治疗2、3个月后患者咳嗽情况、咳嗽症状评分、肺功能及药物不良反应情况。随访患儿复发情况。
结果：经过治疗后，所有7组患儿咳嗽症状评分均呈下降趋势，1秒用力呼气量百分比(FEV1%)和预测呼气峰流量百分比(PEF%)均呈上升趋势。治疗2个月后，Flu +Mon+Ket组咳嗽症状评分明显低于其他组，FEV1%和PEF%明显高于其他组(P<0.05)。治疗2、3个月后，Ket组咳嗽症状评分明显高于其他组，FEV1%、PEF%明显低于其他组(P<0.05)。治疗3个月后，各组咳嗽症状评分、FEV1%、PEF%比较无显著性差异(P>0.05)。7组不良事件发生率均较低，7组间差异无统计学意义(P>0.05)。Ket组咳嗽复发率明显高于其他组(P<0.001)，而其他组咳嗽复发率无显著差异(P>0.0024)。
结论：对于CVA患儿来说，丙酸氟替卡松、孟鲁司特钠、酮替芬联合治疗2个月的临床效果优于两种药物联合治疗和单一药物治疗，并且是安全的。经过3个月的治疗，单用丙酸氟替卡松或单用孟鲁司特钠与药物联合治疗的效果相似。单用酮替芬临床疗效差，且停药后复发率高。
(中日友好医院呼吸与危重症医学科 禹汶伯 摘译 林江涛 审校)
(Zhongguo Dang Dai Er Ke Za Zhi. 2019 Apr;21(4):393-398.)
(Zhongguo Dang Dai Er Ke Za Zhi. 2019 Apr;21(4):393-398.)
Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children.
Zhu XH, Tu JW, Dai JH.
Abstract
OBJECTIVE:To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA).
METHODS:A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence.
RESULTS:After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P<0.05). After 2 and 3 months of treatment, the Ket group had a significantly higher cough symptom score and significantly lower FEV1% and PEF% than the other groups (P<0.05). After 3 months of treatment, there were no significant differences in cough symptom score, FEV1% and PEF% among the other groups (P>0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P>0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P<0.001), while there was no significant difference in this rate among the other groups (P>0.0024).
CONCLUSIONS:For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal.
上一篇：
美伯利单抗在重症难控制嗜酸性粒细胞性哮喘中替代奥玛珠单抗的临床益处
下一篇：
在小鼠哮喘模型中牛乌头碱A可有效缓解过敏性肺部炎症
